Physician profile
Barry S Mann
NPI 1831108844
$16,357.45
in general payments reported to CMS, 2019-2025
49 companies · $1,590 in 2025
The $1,590 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,075 · 2020: $1,993 · 2021: $1,996 · 2022: $5,468 · 2023: $1,639 · 2024: $1,597 · 2025: $1,590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,790 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,790.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $36.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ischemaview, INC. | $3,325.00 | 2022 | |
| Biogen, INC. | $1,107.27 | 2019-2024 | Vumerity, Plegridy, Avonex |
| Lilly USA, LLC | $1,067.09 | 2019-2025 | Emgality, Amyvid, Reyvow |
| Amneal Pharmaceuticals LLC | $974.75 | 2019-2025 | Rytary, Crexont |
| Abbvie INC. | $873.74 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $800.69 | 2019-2025 | Nuplazid |
| Mdd US Operations, LLC | $658.53 | 2019-2025 | Gocovri, Apokyn |
| Neurocrine Biosciences, INC. | $634.78 | 2019-2024 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $609.24 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $500.39 | 2020-2022 | |
| Lundbeck LLC | $398.33 | 2020-2025 | Rexulti |
| Amgen INC. | $369.17 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $361.69 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $361.07 | 2023-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $315.19 | 2020-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.